The treatment of graves' disease in children

Journal of Pediatric Endocrinology and Metabolism

Volumn 19, Issue 9, 2006, Pages 1095-1111

  Rivkees, Scott A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hyperthyroidism; Pediatric; Radio active iodine; Thyroid cancer

Indexed keywords

ANTITHYROID AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IODINE; IODINE 123; IODINE 131; LEVOTHYROXINE; LIVER ENZYME; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROPRANOLOL; PROPYLTHIOURACIL; QUININE; RADIOACTIVE IODINE; THIAMAZOLE; THIONAMIDE; THIOURACIL; VITAMIN D; VITAMIN D DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACNE; AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTHRALGIA; BED REST; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BREAST CANCER; COLON CANCER; COMMON COLD; CONGENITAL MALFORMATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG UPTAKE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; EXOPHTHALMOS; EYE DISEASE; GENETIC DISORDER; GRAVES DISEASE; GROWTH DISORDER; HEALTH CARE COST; HEPATITIS; HUMAN; HYPERPARATHYROIDISM; HYPERTHYROIDISM; HYPOPARATHYROIDISM; IMMUNE DEFICIENCY; LEUKEMIA; LEUKOPENIA; LIVER FAILURE; LOW DRUG DOSE; NAUSEA; NECK PAIN; NEPHROTIC SYNDROME; POLYARTERITIS NODOSA; PRURITUS; RECURRENT LARYNGEAL NERVE PALSY; REMISSION; REVIEW; SALIVATION; SIDE EFFECT; SINGLE DRUG DOSE; SURGICAL RISK; THYROID ADENOMA; THYROID CANCER; THYROID CRISIS; THYROID NODULE; THYROIDECTOMY; THYROIDITIS; TRACHEA COMPRESSION; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA; VASCULITIS; VOCAL CORD PARALYSIS; WEIGHT GAIN;

EID: 33750354498     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2006.19.9.1095     Document Type: Review

References (130)

1. Weetman AP. Graves' disease 1835-2002. Horm Res 2003; 59 (Suppl 1): 114-118.
2. Weetman AP. Graves' disease. N Engl J Med 2000; 343: 1236-1248.
3. Chapman EM. History of the discovery and early use of radioactive iodine. JAMA 1983; 250: 2042-2044.
4. Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352: 905-917.
5. Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves' disease: outcome and treatment. J Pediatr Endocrinol Metab 2003; 16: 1249-1255.
6. Rivkees SA, Sklar C, Freemark M. Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998; 83: 3767-3776.
7. Takashima S, Nomura N, Tanaka H, Itoh Y, Miki K, Harada T. Congenital hypothyroidism: assessment with ultrasound. Am J Neuroradiol 1995; 16: 1117-1123.
8. Wilkins L. Hypothyroidism. In: Wilkins L. The Diagnosis and Treatment of Endocrine Disorders in Children and Adolescence. Springfield, IL: Charles C. Thomas, 1965; 141-150.
9. Fisher DA. Graves' disease in children. Curr Ther Endocrinol Metab 1994; 5: 71-74.
10. Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am 1998; 27: 109-126.
11. LaFranchi S, Mandel SH. Graves' disease in the neonatal period and childhood. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. Philadelphia, PA: J.B. Lippincott, 1995; 1237-1246.
12. Levy WM, Schumacher OP, Gupta M. Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleveland Clin J Med 1988; 55: 373-382.
13. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985; 60: 1019-1024.
14. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997; 82: 1719-1726.
15. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997; 7: 755-760.
16. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000; 85: 3678-3682.
17. Greer MA, Kammer H, Bouma DJ. Short-term antithyroid drug therapy for the thyrotoxicosis of Graves' disease. N Engl J Med 1977; 297: 173-176.
18. Weetman AP. Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nature Clin Pract Endocrinol Metab 2006; 2: 2-3.
19. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Delambre C, Derennes V. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70: 675-679.
20. Garcia-Mayor RV, Paramo C, Luna Cano R, Perez Mendez LF, Galofre JC, Andrade A. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest 1992; 15: 815-820.
21. Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, Lescouarch J, Herry JY, Allannic H. Antithyroid drugs and Graves' disease-prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999; 50: 127-132.
22. 131I) for hyperthyroidism. N Engl J Med 1970; 283: 949-953.
23. 131I) for hyperthyroidism. N Engl J Med 1975; 292: 167-171.
24. Crile G, Schumacher OP. Radioactive iodine treatment of Graves' disease. Results in 32 children under 16 years of age. Am J Dis Child 1965; 110: 501-504.
25. Robertson JS, German CA. Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism. J Nucl Med 1976; 17: 826-835.
26. Williams ED. Biological effects of radiation on the thyroid. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. Philadelphia, PA: J.B. Lippincott Co., 1986; 421-436.
27. Goolden AWG, Davey JB. The ablation of normal thyroid tissue with iodine-131. Br J Radiol 1963; 36: 340-345.
28. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309: 937-941.
29. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid 1997; 7: 247-251.
30. Graham GD, Burman KD. Radioiodine treatment of Graves' disease. An assessment of its potential risks. Ann Intern Med 1986; 105: 900-905.
31. Quimby EM, Feitelberg S, Gross W. Radioactive Nuclides in Medicine and Biology. Lea and Febigir, 1970.
32. 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995; 25: 186-193.
33. Vitti P, Martino E, Aghini-Lombardi F, Rago T, Antonangeli L, Maccherini D, Nanni P, Loviselli A, Balestrieri A, Araneo G, et al. Thyroid volume measurement by ultrasound in children as a tool for the assessment of mild iodine deficiency. J Clin Endocrinol Metab 1994; 79: 600-603.
34. Ueda D. Normal volume of the thyroid gland in children. J Clin Ultrasound 1990; 18: 455-462.
35. Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA. Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab 2001; 86: 1865-1867.
36. Becker DV, Hurley JR. Complications of radioiodine treatment of hyperthyroidism. Semin Nucl Med 1971; 1: 442-460.
37. 131I, antithyroid drugs and KI therapy. J Nucl Med Allied Sci 1977; 21: 23-29.
38. 131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983; 57: 250-253.
39. 131I treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis. Clin Endocrinol (Oxf) 1997; 16: 1-5.
40. Rappaport R, Caplan, DeGroot LJ. Low-dose sodium iodine I 131 therapy in Graves disease. JAMA 1973; 224: 1610-1613.
41. Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 1989; 87: 70-73.
42. Goolden AW, Stewart JS. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 1986; 24: 217-222.
43. 131I in the treatment of Graves' disease. Ohio State Med J 1976; 72: 538-540.
44. Dobyns BM. Radiation effects on the thyroid. Effects vary with dosage and sensitivity of the gland to radiation. RI Med J 1975; 58: 94-97, 122-125.
45. Safa AM. Treatment of hyperthyroidism with a large initial dose of sodium iodine I 131. Arch Intern Med 1975; 135: 673-675.
46. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998; 83: 40-46.
47. Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N. Changes in thyroid volumes in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab 1996; 81: 3257-3260.
48. Hancock LD, Tuttle RM, LeMar H, Baumen J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol (Oxf) 1997; 47: 425-430.
49. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism -prognostic factors for outcome. J Clin Endocrinol Metab 2001; 86: 3611-3617.
50. Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 1995; 5: 243-247.
51. Yoshida K, Aizawa Y, Kaise N, Fukazawa H, Kiso Y, Sayama N, Mori K, Hori H, Abe K. Relationship between thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins years after administration of radioiodine for Graves' disease: retrospective clinical survey. J Clin Endocrinol Invest 1996; 19: 682-686.
52. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 685-687.
53. 131-I: optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med 1979; 20: 847-850.
54. 131I treatment of hyperthyroidism in 73 children and adolescents. J Nucl Med 1964; 5: 81-89.
55. 31-I treatment of hyperthyroidism in 73 children and adolescents: 1967 follow-up. J Nucl Med 1969; 10: 586-590.
56. Kogut MD, Kaplan SA, Collipp PJ, Tiamsic T, Boyle D. Treatment of hyperthyroidism in children: analysis of forty-five patients. N Engl J Med 1965; 272: 217-222.
57. Moll GW Jr, Patel BR. Pediatric Graves' disease: therapeutic options and experience with radioiodine at the University of Mississippi Medical Center. South Med J 1997; 90: 1017-1022.
58. Sheline GE, McCormack KR, Galante M. Thyroid nodules occurring late after treatment of thryotoxicosis with radioiodine. J Clin Endocrinol Metab 1962; 22: 8-17.
59. Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics 2003; 111: 745-749.
60. Goolden AW, Kam KC, Fitzpatrick ML, Munro AJ. Oedema of the neck after ablation of the thyroid with radioactive iodine. Br J Radiol 1986; 59: 583-586.
61. Craswell PW. Vocal cord paresis following radioactive iodine therapy. Br J Clin Pract 1972; 26: 571-572.
62. McDermott MT, Kidd GS, Dodson LE Jr, Hofeldt FD. Radioiodine-induced thyroid storm. Case report and literature review. Am J Med 1983; 75: 353-359.
63. Bondeson AG, Bondeson L, Thompson NW. Hyperparathyroidism after treatment with radioactive iodine: not only a coincidence? Surgery 1989; 106: 1025-1027.
64. Hedman I, Fjalling M, Lindberg S, Lundberg LM, Tisell LE. An assessment of the risk of developing hyperparathyroidism and thyroid disorders subsequent to neck irradiation in middle-aged women. J Surg Oncol 1985; 29: 78-81.
65. 131I treatment for thyrotoxicosis. Acta Chir Scand 1983; 149: 681-686.
66. DeGroot LJ, Gorman CA, Pinchera A, Bartalena L, Marcocci C, Wiersinga WM, Prummel MF, Wartofsky L, Marcocci C. Therapeutic controversies. Retro-orbital radiation and radioactive iodide ablation of the thyroid may be good for Graves' ophthalmopathy. J Clin Endocrinol Metab 1995; 80: 339-340.
67. Tallstedt L, Lundell G. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective. Thyroid 1997; 7: 241-245.
68. Saxena KM, Crawford JD, Talbot NB. Childhood thryotoxicosis: a long term perspective. Br Med J 1964; 2: 1153-1158.
69. LaFranchi S. Thyroiditis and acquired hypothyroidism. Pediatr Ann 1992; 21: 29, 32-39.
70. Barnes HV, Blizzard RM. Antithyroid drug therapy for toxic diffuse goiter (Graves disease): thirty years experience in children and adolescents. J Pediatr 1977; 91: 313-320.
71. Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, Fiore E, Valeriano R, Chiovato L, Rocchi R, Pinchera A. Surgical treatment of Graves' disease: subtotal or total thyroidectomy? Surgery 1996; 120: 1020-1024; discussion 4-5.
72. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338: 73-78.
73. Dolphin GW. The risk of thyroid cancers following irradiation. Health Phys 1968; 15: 219-228.
74. Boice JD Jr. Radiation-induced thyroid cancer-what's new? J Natl Cancer Inst 2005; 97: 703-705.
75. Boice JD Jr. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA 2006; 295: 1060-1062.
76. Ron E, Lubin J, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995; 141: 259-77.
77. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005; 365: 2014-2023.
78. Davis S, Kopecky KJ, Hamilton TE, Onstad L. Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the Hanford nuclear site. JAMA 2004; 292: 2600-2613.
79. 131I: a population-based cohort study in Sweden. Int J Cancer 2003; 106: 580-587.
80. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab 1974; 38: 976-998.
81. Read CH Jr, Tansey MJ, Menda Y. A thirty-six year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 2004; 89: 4229-4233.
82. Boice JD Jr. Radiation and thyroid cancer: what more can be learned? Acta Oncol 1998; 34: 321-324.
83. Saenger EL, Thoma GE, Tompkins EA. Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the Cooperative Thyrotoxicosis Therapy Follow-Up Study. JAMA 1968; 205: 855-862.
84. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD Jr. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998; 280: 347-355.
85. Hall P, Berg G, Bjelkengren G, Boice JD Jr, Ericsson UB, Hallquist A, Lidberg M, Lundell G, Tennvall J, Wiklund K, et al. Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer 1992; 50: 886-890.
86. Toohey RE, Stabin MG. Comparative analysis of dosimetry parameters for nuclear medicine. ORISE Report 99-1064, 1999. In: Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium; 1996; Gatlinburg, TN; 1996; 532-551.
87. Toohey RE, Stabin MG, Watson EE. The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. Radiographics 2000; 20: 533-546.
88. Committee on Health Effects of Exposure to Low Levels of Ionizing Radiations (Beir VII) NRC. Health Effects of Exposure to Low Levels of Ionizing Radiations: Time for Reassessment? Washington, D.C.: National Academy of Science, 1998.
89. Hendee WR, Estimation of radiation risks. BEIR V and its significance for medicine. JAMA 1992; 268: 620-624.
90. Committee on the Biological Effects of Ionizing Radiation (BEIR V) NRC. Health Effects of Exposure to Low Levels of Ionizing Radiation: BEIR V. Washington D.C.: National Academy Press, 1990.
91. 131I for thyroid cancer. J Nucl Med 1976; 17: 460-464.
92. Schull WJ, Otake M, Neel JV. Genetic effects of the atomic bombs: a reappraisal. Science 1981; 213: 1220-1227.
93. http://nobelprize.org/medicine/laureates/1909/index.html
94. Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease? Thyroid 2005; 15: 569-574.
95. Altman RP. Total thyroidectomy for the treatment of Graves' disease in children. J Pediatr Surg 1973; 8: 295-300.
96. Terris DJ, Gourin CG, Chin E. Minimally invasive thyroidectomy: basic and advanced techniques. Laryngoscope 2006; 116: 350-356.
97. Ching T, Warden MJ, Fefferman RA. Thyroid surgery in children and teenagers. Arch Otolaryngol 1977; 103: 544-546.
98. Buckingham BA, Costin G, Roe TF, Weitzman JJ, Kogut MD. Hyperthyroidism in children. A reevaluation of treatment. Am J Dis Child 1981; 135: 112-117.
99. Rudberg C, Johansson H, Akerstrom G, Tuvemo T, Karlsson FA. Graves' disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol 1996; 134: 710-715.
100. Harrison TS. Thyroid surgery in historical perspective. J Med Liban 1970; 23: 537-551.
101. Osler W. Graves Disease. In: The Practice of Medicine. New York: Appleton, 1935; 900-907.
102. Talbot NB, McArthur JW, Crawford JD. Functional Endocrinology: From Birth to Adolescence. Cambridge, MA: Harvard University Press, 1952; 1-51.
103. Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin North Am 1998; 27: 225-247.
104. Cooper DS. Which anti-thyroid drug? Am J Med 1986; 80: 1165-1168.
105. Dallas JS, Foley TP Jr. Hyperthyroidism. In: Lifshitz F, ed. Pediatric Endocrinology. New York: Marcel Dekker, Inc., 1996; 401-414.
106. Mashio Y, Beniko M, Ikota A, Mizumoto H, Kunita H. Treatment of hyperthyroidsim with a single daily dose of methimazole. Acta Endocrinol Suppl (Copenh) 1988; 119: 139-144.
107. Mashio Y, Beniko M, Matsuda A, Koizumi S, Matsuya K, Mizumoto H, Ikota A, Kunita H. Treatment of hyperthyroidism with a small single daily dose of methimazole: a prospective long-term follow-up study. Endocr J 1997; 44: 553-558.
108. Shiroozu A, Okamura K, Ikenoue H, Sato K, Nakashima T, Yoshinari M, Fujishima M, Yoshizumi T. Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 1986; 63: 125-128.
109. Greer MA, Meihoff WC, Studer H. Treatment of hyperthyroidism with a single daily dose of propylthiouracil. N Engl J Med 1965; 272: 888-891.
110. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Invest 1996; 26: 59-63.
111. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, Fishman SJ, Larsen PR. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000; 343: 185-189.
112. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987; 64: 1241-1245.
113. Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, Savage CO, Franklyn JA. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf) 2004; 60: 671-675.
114. Guma M, Olive A, Juan M, Salinas I. ANCA antibodies in Graves' disease. Ann Rheum Dis 2002; 61: 90-91.
115. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 2005; 38: 93-103.
116. Poomthavorn P, Mahachoklertwattana P, Tapaneya-Olarn W, Chuansumrit A, Chunharas A. Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease. J Med Assoc Thai 2002; 85 (Suppl 4): S1295-1301.
117. Fujieda M, Suzuki K, Sato H, Hattori M, Wada N, Tsuchiya M, Okamoto N, Murata T, Matsudaira M, Shimizu M, Ohta K, Naruse K, Sugihara S, Wakiguchi H. Epitope analysis of myeloperoxidase-specific antineutrophil cytoplasmic autoantibodies (MPO-ANCA) in childhood onset Graves' disease treated with propylthiouracil. Clin Nephrol 2005; 63: 437-445.
118. Merkel PA. Drugs associated with vasculitis. Curr Opin Rheumatol 1998; 10: 45-50.
119. Crawford JD. Hyperthyoidism in children. A reevaluation of treatment. Am J Dis Child 1981; 135: 109-110.
120. Hung W, Wilkins L, Blizzard RM. Medical therapy of thyrotoxicosis in children. Pediatrics 1962; 30: 17-26.
121. Vaidya VA, Bongiovanni AM, Parks JS, Tenore A, Kirkland RT. Twenty-two years experience in the medical management of juvenile thyrotoxicosis. Pediatrics 1974; 54: 565-570.
122. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7: 369-375.
123. Kim WB, Chung HK, Lee HK, Kohn LD, Tahara K, Cho BY. Changes in epitopes for thyroid-stimulating antibodies in Graves' disease sera during treatment of hyperthyroidism: therapeutic implications. J Clin Endocrinol Metab 1997; 82: 1953-1959.
124. Davies T, Roti E, Braverman LE, DeGroot LJ. Thyroid controversy-stimulating antibodies. J Clin Endocrinol Metab 1998; 83: 3777-3785.
125. Rapoport B, Greenspan FS, Filetti S, Pepitone M. Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin. J Clin Endocrinol Metab 1984; 58: 332-338.
126. Wilson R, McKilop JH, Henderson N, Pearson DW, Thomson JA. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease. Clin Endocrinol (Oxf) 1986; 25: 151-156.
127. Bouma DJ, Kammer H, Greer MA. Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves' disease. J Clin Endocrinol Metab 1982; 55: 1138-1142.
128. Bing RF. Early remission in thyrotoxicosis produced by short course of treatment. Acta Endocrinol (Copenh) 1982; Suppl 100: 221-223.
129. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Delambre C, Derennes V. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70: 675-679.
130. Garcia-Mayor RV, Paramo C, Luna Cano R, Perez Mendez LF, Galofre JC, Andrade A. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Clin Endocrinol Invest 1992; 15: 815-820.